Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset

Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset

Background: This phase IIIb, open-label study enrolled patients from nine Asian and Middle Eastern countries to evaluate the safety and efficacy of the combination therapy in underrepresented patient populations from the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2). Here, we report the Taiwa...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan-Ching Chang, Kun-Ming Rau, Dar-Ren Chen, Tsu-Yi Chao, Ming-Feng Hou, Chiun-Sheng Huang*
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-07-01
Series:Journal of Cancer Research and Practice
Subjects:
asia
everolimus
exemestane
hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer
taiwan
Online Access:https://journals.lww.com/10.4103ejcrp.eJCRP-D-23-00008
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.lww.com/10.4103ejcrp.eJCRP-D-23-00008

Similar Items